Переходьте в офлайн за допомогою програми Player FM !
AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA
Manage episode 450201726 series 2134816
We’ve got to keep our eye on the pipeline. What do the latest data tell us about two drug candidates? Durga Borkar, MD, MMCi, reviews data from a phase 2 study assessing the safety and efficacy ONL1204 (ONL Therapeutics) delivered prior to RRD surgery. Did injecting ONL1204, which prevents Fas activation, lead to any postsurgical differences? Alex Melamud stops by to discuss the phase 2/3 SAGA study assessing the safety and efficacy of gildeuretinol (Alkeus Pharmaceuticals), an oral agent for the treatment of geographic atrophy. Can this drug succeed where other oral options in retina have failed?
190 епізодів
Manage episode 450201726 series 2134816
We’ve got to keep our eye on the pipeline. What do the latest data tell us about two drug candidates? Durga Borkar, MD, MMCi, reviews data from a phase 2 study assessing the safety and efficacy ONL1204 (ONL Therapeutics) delivered prior to RRD surgery. Did injecting ONL1204, which prevents Fas activation, lead to any postsurgical differences? Alex Melamud stops by to discuss the phase 2/3 SAGA study assessing the safety and efficacy of gildeuretinol (Alkeus Pharmaceuticals), an oral agent for the treatment of geographic atrophy. Can this drug succeed where other oral options in retina have failed?
190 епізодів
Усі епізоди
×Ласкаво просимо до Player FM!
Player FM сканує Інтернет для отримання високоякісних подкастів, щоб ви могли насолоджуватися ними зараз. Це найкращий додаток для подкастів, який працює на Android, iPhone і веб-сторінці. Реєстрація для синхронізації підписок між пристроями.